Key clinical point: Patients with myasthenia gravis who have not responded to eculizumab within 12 weeks may respond with further treatment.
Major finding: At week 130, the least-squares mean percentage changes from baseline in MG-ADL score were −61.9% and −47.5% in early and late MG-ADL responders, respectively.
Study details: A post hoc analysis of 98 patients with myasthenia gravis who participated in the REGAIN trial and its extension.
Disclosures: Study funding was provided by Alexion Pharmaceuticals (the developer of eculizumab), the CDC, and the NIH. Dr. Howard reported receiving research support and consulting fees or honoraria from Alexion and several other pharmaceutical companies. Several other authors reported financial relationships with Alexion and other pharmaceutical companies; two authors are employees of Alexion.
Howard J et al. AANEM 2019. Unnumbered Abstract.